# Kirby Corp: financial statements, quarterly

KEX · NYSE · CIK 56047 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kex.md) · [Financials](/companies/kex/financials.md) · [Filings](/companies/kex/filings.md) · [Insiders](/companies/kex/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kex/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [765](/filings/0000950170-24-124726.md) | [799 d](/filings/0001193125-26-054016.md) | [808](/filings/0000950170-25-068858.md) | [824](/filings/0000950170-25-106370.md) | [831](/filings/0001193125-25-273962.md) | [802 d](/filings/0001193125-26-054016.md) | [786](/filings/0001193125-26-214839.md) | [855](/filings/0001193125-26-334946.md) | [871](/filings/0001193125-25-273962.md) | [852 d](/filings/0001193125-26-054016.md) | [844](/filings/0001193125-26-214839.md) | [922](/filings/0001193125-26-334946.md) |
| Selling, general and administrative | $m | [79.1](/filings/0000950170-24-124726.md) | [84.3 d](/filings/0001193125-26-054016.md) | [90.2](/filings/0000950170-25-068858.md) | [80.4](/filings/0000950170-25-106370.md) | [84.1](/filings/0001193125-25-273962.md) | [82.4 d](/filings/0001193125-26-054016.md) | [95.3](/filings/0001193125-26-214839.md) | [85.8](/filings/0001193125-26-334946.md) | [87.8](/filings/0001193125-25-273962.md) | [87.4 d](/filings/0001193125-26-054016.md) | [101](/filings/0001193125-26-214839.md) | [88.7](/filings/0001193125-26-334946.md) |
| Operating income | $m | [93.5](/filings/0000950170-24-124726.md) | [92.8 d](/filings/0001193125-26-054016.md) | [102](/filings/0000950170-25-068858.md) | [120](/filings/0000950170-25-106370.md) | [127](/filings/0001193125-25-273962.md) | [50.1 d](/filings/0001193125-26-054016.md) | [106](/filings/0001193125-26-214839.md) | [132](/filings/0001193125-26-334946.md) | [129](/filings/0001193125-25-273962.md) | [130 d](/filings/0001193125-26-054016.md) | [108](/filings/0001193125-26-214839.md) | [122](/filings/0001193125-26-334946.md) |
| Interest expense | $m | [13.4](/filings/0000950170-24-124726.md) | [13.1 d](/filings/0001193125-26-054016.md) | [13.2](/filings/0000950170-25-068858.md) | [12.8](/filings/0000950170-25-106370.md) | [12.5](/filings/0001193125-25-273962.md) | [10.7 d](/filings/0001193125-26-054016.md) | [10.5](/filings/0001193125-26-214839.md) | [12.7](/filings/0001193125-26-334946.md) | [11.8](/filings/0001193125-25-273962.md) | [11.2 d](/filings/0001193125-26-054016.md) | [10.3](/filings/0001193125-26-214839.md) | [11.0](/filings/0001193125-26-334946.md) |
| Income tax | $m | [18.7](/filings/0000950170-24-124726.md) | [19.5 d](/filings/0001193125-26-054016.md) | [21.7](/filings/0000950170-25-068858.md) | [26.8](/filings/0000950170-25-106370.md) | [27.4](/filings/0001193125-25-273962.md) | [0.0 d](/filings/0001193125-26-054016.md) | [24.1](/filings/0001193125-26-214839.md) | [29.6](/filings/0001193125-26-334946.md) | [30.2](/filings/0001193125-25-273962.md) | [32.2 d](/filings/0001193125-26-054016.md) | [23.4](/filings/0001193125-26-214839.md) | [28.6](/filings/0001193125-26-334946.md) |
| Net income | $m | [63.0](/filings/0000950170-24-124726.md) | [61.9 d](/filings/0001193125-26-054016.md) | [70.1](/filings/0000950170-25-068858.md) | [83.9](/filings/0000950170-25-106370.md) | [90.0](/filings/0001193125-25-273962.md) | [42.8 d](/filings/0001193125-26-054016.md) | [76.0](/filings/0001193125-26-214839.md) | [94.3](/filings/0001193125-26-334946.md) | [92.5](/filings/0001193125-25-273962.md) | [91.8 d](/filings/0001193125-26-054016.md) | [81.2](/filings/0001193125-26-214839.md) | [89.7](/filings/0001193125-26-334946.md) |
| Diluted EPS | $ per share | [1.05](/filings/0000950170-24-124726.md) | not reported | [1.19](/filings/0000950170-25-068858.md) | [1.43](/filings/0000950170-25-106370.md) | [1.55](/filings/0001193125-25-273962.md) | not reported | [1.33](/filings/0001193125-26-214839.md) | [1.67](/filings/0001193125-26-334946.md) | [1.65](/filings/0001193125-25-273962.md) | not reported | [1.50](/filings/0001193125-26-214839.md) | [1.67](/filings/0001193125-26-334946.md) |
| Basic EPS | $ per share | [1.06](/filings/0000950170-24-124726.md) | not reported | [1.20](/filings/0000950170-25-068858.md) | [1.44](/filings/0000950170-25-106370.md) | [1.56](/filings/0001193125-25-273962.md) | not reported | [1.33](/filings/0001193125-26-214839.md) | [1.68](/filings/0001193125-26-334946.md) | [1.66](/filings/0001193125-25-273962.md) | not reported | [1.51](/filings/0001193125-26-214839.md) | [1.68](/filings/0001193125-26-334946.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [42.1](/filings/0000950170-23-059177.md) | [32.6](/filings/0000950170-25-022012.md) | [75.2](/filings/0000950170-24-053690.md) | [53.5](/filings/0000950170-24-094676.md) | [67.1](/filings/0000950170-24-124726.md) | [74.4](/filings/0001193125-26-054016.md) | [51.1](/filings/0000950170-25-068858.md) | [68.4](/filings/0000950170-25-106370.md) | [47.0](/filings/0001193125-25-273962.md) | [78.8](/filings/0001193125-26-334946.md) | [58.0](/filings/0001193125-26-214839.md) | [39.0](/filings/0001193125-26-334946.md) |
| Current assets | $m | [1,196](/filings/0000950170-23-059177.md) | [1,135](/filings/0000950170-25-022012.md) | [1,175](/filings/0000950170-24-053690.md) | [1,167](/filings/0000950170-24-094676.md) | [1,164](/filings/0000950170-24-124726.md) | [1,069](/filings/0001193125-26-054016.md) | [1,102](/filings/0000950170-25-068858.md) | [1,185](/filings/0000950170-25-106370.md) | [1,160](/filings/0001193125-25-273962.md) | [1,078](/filings/0001193125-26-334946.md) | [1,142](/filings/0001193125-26-214839.md) | [1,240](/filings/0001193125-26-334946.md) |
| Total assets | $m | [5,683](/filings/0000950170-23-059177.md) | [5,722](/filings/0000950170-25-022012.md) | [5,776](/filings/0000950170-24-053690.md) | [5,866](/filings/0000950170-24-094676.md) | [5,871](/filings/0000950170-24-124726.md) | [5,852](/filings/0001193125-26-054016.md) | [6,015](/filings/0000950170-25-068858.md) | [6,080](/filings/0000950170-25-106370.md) | [6,064](/filings/0001193125-25-273962.md) | [6,008](/filings/0001193125-26-334946.md) | [6,119](/filings/0001193125-26-214839.md) | [6,220](/filings/0001193125-26-334946.md) |
| Current liabilities | $m | [636](/filings/0000950170-23-059177.md) | [676](/filings/0000950170-25-022012.md) | [650](/filings/0000950170-24-053690.md) | [685](/filings/0000950170-24-094676.md) | [698](/filings/0000950170-24-124726.md) | [735](/filings/0001193125-26-054016.md) | [699](/filings/0000950170-25-068858.md) | [679](/filings/0000950170-25-106370.md) | [684](/filings/0001193125-25-273962.md) | [707](/filings/0001193125-26-334946.md) | [717](/filings/0001193125-26-214839.md) | [736](/filings/0001193125-26-334946.md) |
| Long-term debt | $m | [1,058](/filings/0000950170-23-059177.md) | [1,009](/filings/0000950170-25-022012.md) | [1,052](/filings/0000950170-24-053690.md) | [1,039](/filings/0000950170-24-094676.md) | [970](/filings/0000950170-24-124726.md) | [867](/filings/0001193125-26-054016.md) | [1,091](/filings/0000950170-25-068858.md) | [1,111](/filings/0000950170-25-106370.md) | [1,042](/filings/0001193125-25-273962.md) | [912](/filings/0001193125-26-334946.md) | [977](/filings/0001193125-26-214839.md) | [1,031](/filings/0001193125-26-334946.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3,157](/filings/0000950170-23-059177.md) | [3,185](/filings/0000950170-25-022012.md) | [3,216](/filings/0000950170-24-053690.md) | [3,261](/filings/0000950170-24-094676.md) | [3,302](/filings/0000950170-24-124726.md) | [3,352](/filings/0001193125-26-054016.md) | [3,326](/filings/0000950170-25-068858.md) | [3,388](/filings/0000950170-25-106370.md) | [3,361](/filings/0001193125-25-273962.md) | [3,381](/filings/0001193125-26-334946.md) | [3,414](/filings/0001193125-26-214839.md) | [3,443](/filings/0001193125-26-334946.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [96.3 d](/filings/0000950170-24-124726.md) | [216 d](/filings/0001193125-26-054016.md) | [123](/filings/0000950170-25-068858.md) | [179 d](/filings/0000950170-25-106370.md) | [207 d](/filings/0001193125-25-273962.md) | [247 d](/filings/0001193125-26-054016.md) | [36.5](/filings/0001193125-26-214839.md) | [93.9 d](/filings/0001193125-26-334946.md) | [228 d](/filings/0001193125-25-273962.md) | [312 d](/filings/0001193125-26-054016.md) | [97.7](/filings/0001193125-26-214839.md) | [72.3 d](/filings/0001193125-26-334946.md) |
| Capital expenditure | $m | [104 d](/filings/0000950170-24-124726.md) | [127 d](/filings/0001193125-26-054016.md) | [81.0](/filings/0000950170-25-068858.md) | [88.6 d](/filings/0000950170-25-106370.md) | [76.4 d](/filings/0001193125-25-273962.md) | [96.7 d](/filings/0001193125-26-054016.md) | [78.7](/filings/0001193125-26-214839.md) | [71.5 d](/filings/0001193125-26-334946.md) | [67.3 d](/filings/0001193125-25-273962.md) | [47.0 d](/filings/0001193125-26-054016.md) | [48.3](/filings/0001193125-26-214839.md) | [71.5 d](/filings/0001193125-26-334946.md) |
| Share repurchases | $m | [23.3 d](/filings/0000950170-24-124726.md) | [51.9 d](/filings/0001193125-26-054016.md) | [41.8](/filings/0000950170-25-068858.md) | [43.7 d](/filings/0000950170-25-106370.md) | [55.8 d](/filings/0001193125-25-273962.md) | [33.3 d](/filings/0001193125-26-054016.md) | [101](/filings/0001193125-26-214839.md) | [31.2 d](/filings/0001193125-26-334946.md) | [120 d](/filings/0001193125-25-273962.md) | [102 d](/filings/0001193125-26-054016.md) | [52.7](/filings/0001193125-26-214839.md) | [59.7 d](/filings/0001193125-26-334946.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [60.2](/filings/0000950170-23-059177.md) | [60.3](/filings/0000950170-24-053690.md) | [60.1](/filings/0000950170-24-094676.md) | [59.7](/filings/0000950170-24-124726.md) | [58.8](/filings/0000950170-25-068858.md) | [58.6](/filings/0000950170-25-106370.md) | [58.2](/filings/0001193125-25-273962.md) | [57.3](/filings/0001193125-26-214839.md) | [56.4](/filings/0001193125-26-334946.md) | [56.0](/filings/0001193125-25-273962.md) | [54.0](/filings/0001193125-26-214839.md) | [53.7](/filings/0001193125-26-334946.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 52,800,000 at 2026-08-04, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-334946.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.